While medical cannabis is often used to ease pain or nausea, an Israeli-American biopharmaceutical company is developing medicines containing cannabinoids — chemical compounds from cannabis plants — to treat conditions including diabetes, inflammatory diseases (like arthritis, atherosclerosis and ulcerative colitis) and cardiovascular disorders.
ISA Scientific recently signed an exclusive worldwide licensing and collaboration agreement to establish therapies containing a specific cannabinoid called cannabidiol (CBD), with Yissum, the technology-transfer company of the Hebrew University of Jerusalem, Hadasit, the technology-transfer company of the Hadassah Medical Organization in Jerusalem, and the Kennedy Trust for Rheumatology Research (KIR) in the United Kingdom.
The licensed intellectual property is the result of many years of research and collaboration between renowned cannabinoid scientists, Raphael Mechoulam, Professor of medicinal chemistry, and Ruth Gallily, Professor of immunology, both from the Hebrew University; the distinguished immunologist, Professor Sir Marc Feldman, Director of the Kennedy Institute of Rheumatology; and prominent physicians and scientists at Hadassah Professors Chaim Lotan and Ronen Durst, and Dr. Lola Weiss.
Immune Pharmaceuticals Inc. (NASDAQ: IMNP) announced today that it has entered into a binding memorandum of understanding with Yissum, the Technology Transfer Company of the Hebrew University of Jerusalem, to license certain of Yissum's patents in order to facilitate the development of a topical nanoparticle formulation of Immune's neuropathic pain drug, AmiKet™.
The technology that Immune will be licensing was invented by Professor Simon Benita, from the Institute for Drug Research, the School of Pharmacy, and Faculty of Medicine at the Hebrew University, a renowned expert in development of drug delivery technology, and a primary inventor of NanomAbs, an antibody nanoparticle conjugate technology to deliver cancer drugs, already licensed by Immune from Yissum.
While the world is moving into a new era of Internet of Things (IoT), where all devices will be connected, there is a constant growing demand for cyber security innovations that will allow a balance between user privacy to the sharing of information. We believe that collaboration between the students and researchers of the Hebrew University and Kaspersky could yield innovations that would build tomorrow’s security demands” said Tamir Huberman, VP Business Development, Yissum
According to Yissum CEO Yaacov Michlin, 65 licensing and license option agreements were signed in 2014 with many different national companies, and a total of 596 agreements of various types were signed (including confidentiality agreements that precede deals, research services agreements, etc.). This is an increase in two parameters in comparison with 2013. Nine companies were founded on the basis of technology originating at the university, and raised $9 million.
Kaspersky Lab announced a brand-new global initiative designed to identify and nurture new talent for the security industry. The Security Startup Challenge (SSC) is a mentor-driven acceleration program developed and implemented by the Kaspersky Academy, in partnership with venture industry leaders, Mangrove Capital Partners and the ABRT Venture Fund to provide startups with access to cutting-edge business, cybersecurity and cross-industry expertise from around the world.
SSC will be held in a number of cities around the world. In Israel the program will be held in cooperation with Jnext of the Jerusalem Development Authority, the Jerusalem Municipality and the Ministry of Jerusalem and Diaspora Affairs, which gives the framework of services, resources, support and assistance to startup entrepreneurs and young technology companies, with the Hebrew University of Jerusalem, which operates one of the world's leading Schools of Computer Science and Engineering and with Yissum, the Technology Transfer Company of The Hebrew University of Jerusalem.
The Global Innovation Award has a top prize of $1 million.
The Hebrew University tech transfer company will collaborate on a novel delivery system.
Know what keeps Ruth Gallily up at night? The Hebrew University immunology professor emerita is frustrated to know how many people could benefit from medical cannabis if only more countries would make it available in pharmacies.
Blue-and-white technology converts toxic hydrocarbons into benign material, without further harm to flora and fauna.
The technology, which was patented and commercialized by Hebrew University’s technology transfer company Yissum, was sold to the Swiss firm Man Oil Group about a year ago.
The New Technology invented by Prof. Yoel Sasson and Dr. Uri Stoin was licensed to Swiss Co. Man Oil Group.
EyeMusic- A New Tachnology by Prof. Amir Amedi gives a new meaning to sound and vision for the blind.
Integra Holdings, the biotechnology holdings company of Yissum, the technology transfer company of the Hebrew University of Jerusalem, has received a $3 million investment from China's Guangxi Wuzhou Pharmaceutical Group. The funds raised will be used to advance Integra Holdings’ existing portfolio companies and to create new companies, based on promising projects originating from the Hebrew University.
The BreedIT system is based in part by research conducted by Professors Haim Rabinowitch and Nachum Kedar of Hebrew University, most famous for their work in developing popular strains of cherry tomatoes and perfecting long-life tomatoes that contain a ripening inhibitor gene to guarantee a longer shelf life.
The new technology, according to BreedIT CEO Dr. Oded Sagee, is essential to the development of the medical marijuana industry – which Sagee believes is set for a major worldwide expansion. “We decided to develop an organized breeding program to assist breeders to develop new breeds of cannabis,”
Israeli Tech Transfer Offices are world leaders in their ability to turn ealy-stage inventions to products on market. [Hebrew article).
Lockheed Martin Israel Ltd. and Yissum Research Development Company Ltd., the technology transfer company of the Hebrew University of Jerusalem, have signed an agreement to conduct joint collaborative research. The collaboration will focus on basic and applicable scientific research in areas such as quantum information sciences and material sciences, and other areas.
A top US health agency is working with an Israeli start-up to develop solutions to ‘flesh-eating’ septic bio-threats
We are happy to share with you some of the exciting events of our Year of Jubilee.
Hyrax licenses the technology for YIssum to produce new printers that will use silver-based inks for to revolutionize conductive printing.
The first gateway for Korean companies to the world of Israeli Academic Innovation.